PMCPA Case Analysis

Over 2,000 real rulings β€” analysed for what they mean to your team. Published every day.

All Cases PMCPA Case of the Week PMCPA Cases

Showing 1914 cases

2019
CASE
Consilient Health ⭐ Case of the Week

Consilient app preview on Google Play ruled public advertising of POM (InVita D3)

Vitamin D Vitality app previews on Google Play showed InVita D3 and PI before download. Panel ruled this advertised a POM to…

2020
CASE
AUTH/3396/10/20 Daiichi-Sankyo UK

Daiichi-Sankyo breached ABPI Code over out-of-date competitor safety symbol in Nilemdo FOC scheme material (AUTH/3396/10/20)

Nilemdo FOC scheme material continued to show Praluent with a black triangle after it was removed from the SPC. PMCPA found the…

2019
CASE
Takeda

Takeda: β€˜ASH 2020 Highlights’ webinar ruled promotional for an unlicensed indication (ixazomib frontline myeloma)

PMCPA ruled Takeda’s ASH highlights webinar was not genuine scientific exchange and promoted ixazomib for an unlicensed frontline myeloma indication. Breaches of…

2019
CASE
AUTH/3275/10/19 Ever Pharma

Ever Pharma found in breach over Dacepton stability and cost-saving claims (AUTH/3275/10/19)

Ever Pharma’s Dacepton leavepieces breached the ABPI Code for misleading stability and cost-saving claims that omitted microbiological contamination caveats from the SPC.…

2021
CASE
AUTH/3487/3/21 Sanofi

Sanofi: flu vaccine ordering emails misled on NHS reimbursement and disparaged NHS bodies (AUTH/3487/3/21)

Sanofi emails to GP customers and an NHS manager suggested QIVe orders were β€œfully reimbursable” and criticised local NHS interpretation. PMCPA found…

2021
CASE
AUTH/3491/3/21 Sanofi ⭐ Case of the Week

AUTH/3491/3/21: Complainant v Sanofi β€” Suliqua off-licence promotion allegation (No breach)

Anonymous health professional alleged Sanofi promoted Suliqua for use alongside basal insulin, risking overdose. Panel found insufficient evidence and ruled no breach…

2021
CASE
AUTH/3507/5/21 Daiichi-Sankyo UK

Daiichi-Sankyo: Lixiana symposium recording on Vimeo viewable by the public (AUTH/3507/5/21 & AUTH/3513/5/21)

A sponsored symposium recording about Lixiana was uploaded to Vimeo with incorrect privacy settings, making it viewable by the public. Breach found…

2021
CASE
AUTH/3516/5/21 Chiesi

Chiesi webinar: prescribing information not readable/long enough and Trimbow described as β€œsafe” (AUTH/3516/5/21)

A health professional complained about a Chiesi asthma webinar. The Panel found breaches for unreadable/too-brief prescribing information and describing Trimbow as β€œsafe”.…

2021
CASE
AUTH/3583/11/21 ALK-AbellΓ³

AUTH/3583/11/21: Instagram β€˜awards’ story featuring Itulazax imagery β€” no breach after appeal (ALK-AbellΓ³)

A creative agency posted Itulazax (POM) campaign frames on Instagram after the contract ended. Panel found a Clause 3.2 breach, but the…

2021
CASE
AUTH/3514/5/21 AstraZeneca

AstraZeneca advisory board: β€˜scientific exchange’ terminology and late-signed consultant contract (AUTH/3514/5/21)

Ex-employee alleged a post-ASH β€˜scientific exchange’ was disguised promotion. Panel found meeting non-promotional but ruled breaches for high standards (misleading terminology) and…

2022
CASE
AUTH/3609/2/22 Britannia Pharmaceuticals ⭐ Case of the Week

Britannia Pharmaceuticals: prescribing information temporarily inaccessible on APO-go website (third-party error) (AUTH/3609/2/22)

A third-party web contractor inadvertently removed APO-go prescribing information during remediation work, leaving PI inaccessible for over 24 hours. PMCPA ruled a…

2023
CASE
AUTH/3738/2/23 Novo Nordisk

Novo Nordisk voluntary admission: failure to appropriately certify collaborative working website hub (AUTH/3738/2/23)

Novo Nordisk admitted certification failures for a password-protected obesity/weight management hub hosted on an association website. Panel found poor oversight and ruled…

2022
CASE
AUTH/3626/3/22 Novartis Pharmaceuticals UK

Novartis: Leqvio online supplementβ€”missing black triangle on standalone articles and printed versions lacked prescribing information (AUTH/3626/3/22)

Four Novartis-funded Leqvio (inclisiran) supplement articles were accessible without the landing page and omitted the black triangle; printed versions appeared to lack…

2022
CASE
AUTH/3666/6/22 Daiichi-Sankyo UK

Daiichi Sankyo breached ABPI Code over HSJ sponsored article transparency (AUTH/3666/6/22)

HSJ β€œsponsored” article on AF/stroke was not clear at the outset that it was written by a senior Daiichi Sankyo employee. Breach…

2022
CASE
AUTH/3661/6/22 AstraZeneca

AstraZeneca breached Clause 8.1 over Forxiga website certification differences between desktop and mobile (AUTH/3661/6/22)

AstraZeneca was ruled in breach of Clause 8.1 after the Forxiga diabetes webpage differed between desktop and mobile (audience banner shown on…

Ask questions about any PMCPA case

Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases β€” ask about precedents, clauses, and how they apply to your situation.

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training